Phathom Pharmaceuticals (PHAT) announces that effective immediately, CVS Caremark (CVS) has added VOQUEZNA tablets to its commercial formularies. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn. VOQUEZNA is the first and only FDA-approved potassium-competitive acid blocker available in the United States. Over 116 million commercially covered lives are now estimated to have access to VOQUEZNA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
- Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
- Phathom Pharmaceuticals announces FDA approval of VOQUEZNA
- Biotech Alert: Searches spiking for these stocks today